Encodes A Microbial Polypeptide Patents (Class 536/23.7)
-
Patent number: 11592396Abstract: The present invention provides compositions and methods for imaging tumor resections.Type: GrantFiled: March 25, 2020Date of Patent: February 28, 2023Assignee: Lumicell, Inc.Inventors: W. David Lee, Moungi G. Bawendi, Jorge Ferrer
-
Patent number: 11591627Abstract: The disclosure relates, in some aspects, to compositions and methods useful for production of nitrated aromatic molecules. The disclosure is based, in part, on whole cell systems expressing artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes. In some aspects, the disclosure relates to methods of producing nitrated aromatic molecules in whole cell systems having artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes.Type: GrantFiled: March 21, 2019Date of Patent: February 28, 2023Assignee: University of Florida Research Foundation, IncorporatedInventors: Yousong Ding, Ran Zuo
-
Patent number: 11571458Abstract: Methods are described for increasing levels of healthy vaginal bacteria by treating the vaginal mucosa with bacteriocins derived from Lactobacillus paragasseri, Lactobacillus gasseri, and other bacterial strains. The bacteriocins are surprisingly advantageous as being selectively active against Lactobacillus iners but relatively inactive against H2O2-producing Lactobacillus species. Because L. iners is involved in the onset and maintenance of vaginal dysbiosis, selective removal of this bacterium from the vaginal microbiome treats or prevents conditions associated with vaginal dysbiosis, such as bacterial vaginosis and its sequelae.Type: GrantFiled: February 26, 2021Date of Patent: February 7, 2023Assignee: Osel, Inc.Inventors: Thomas P. Parks, Trine Nilsen
-
Patent number: 11491239Abstract: Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.Type: GrantFiled: December 17, 2018Date of Patent: November 8, 2022Assignees: The Medical College of Wisconsin, Inc., Wisconsin Alumni Research FoundationInventors: Joseph T. Barbieri, Eric A. Johnson, Sabine Pellett, William H. Tepp, Amanda Przedpelski
-
Patent number: 11479588Abstract: The disclosure discloses cathelicidin-expressing lactic acid bacteria, and belongs to the technical field of genetic engineering. The disclosure constructs Lactococcus. lactis and Lactobacillus. plantarum expressing a CRAMP protein by optimizing the nucleotide sequence of the CRAMP protein. The Lactobacillus constructed in the disclosure can be used to prepare a vaccine for regulation of intestinal flora disorder, and has advantages in regulation of intestinal flora and intestinal immune response and maintenance. An anaculture can be directly taken as an oral vaccine to stimulate mice and cause a strong cellular immune response. The recombinant L. lactis can be used as a new oral vaccine product with good industrial prospects, plays a positive role in reducing intestinal inflammation, and has important practical significance for promoting health development of the intestinal tract.Type: GrantFiled: November 18, 2021Date of Patent: October 25, 2022Assignee: Jiangnan UniversityInventors: Jia Sun, Li-Long Pan, Diana Julien, Ming Zhang, Wei Chen, Hao Zhang
-
Patent number: 11332708Abstract: The present disclosure relates to a microorganism of the genus Corynebacterium producing 5?-xanthosine monophosphate and a method for producing 5?-xanthosine monophosphate using the same.Type: GrantFiled: October 21, 2020Date of Patent: May 17, 2022Assignee: CJ CHEILJEDANG CORPORATIONInventors: Min Ji Baek, Ji Hye Lee, Boram Lim, Byoung Hoon Yoon, Jeong Eun Lee, Su-bin Lim, Jaeho Jeong
-
Patent number: 11248269Abstract: The invention relates, in part, to methods to identify the presence and/or level of a pathogenic V. parahaemolyticus bacterium in a subject or in or on a substrate. Methods are provided that, in part, permit detection of infection of a subject, or contamination of a substrate by pathogenic V. parahaemolyticus bacteria.Type: GrantFiled: March 5, 2016Date of Patent: February 15, 2022Assignee: UNIVERSITY OF NEW HAMPSHIREInventors: Cheryl Whistler, Jeffrey Allister Hall, Feng Xu
-
Patent number: 11180768Abstract: The invention provides DNA molecules and constructs, including their nucleotide sequences, useful for modulating gene expression in plants and plant cells. Transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides are also provided, as are methods of their use.Type: GrantFiled: December 20, 2019Date of Patent: November 23, 2021Assignee: Monsanto Technology LLCInventors: Stanislaw Flasinski, Barrett C. Foat, Mohammed Oufattole, Randall W. Shultz, Xiaoping Wei, Wei Wu, Shiaw-Pyng Yang
-
Patent number: 11104966Abstract: A method for amplifying and detecting microorganisms, such as species of Listeria, is described. The method utilizes gene-matched enrichment media and PCR-based detection. The enrichment media is spent media produced using a modified microorganism containing a plurality of mutations in a selected gene such that the modified microorganism does not contain the PCR signature. Thus, PCR detects only the amplified microorganism of interest, not the modified microorganism. Exemplary methods and kits for amplification and detection of Listeria species are described.Type: GrantFiled: September 14, 2018Date of Patent: August 31, 2021Assignee: Battelle Memorial InstituteInventors: Richard M. Ozanich, Janine R. Hutchison, Kristin D. Victry, Becky M. Hess
-
Patent number: 11053510Abstract: The invention provides recombinant DNA molecules and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants. The invention also provides transgenic plants, plant cells, plant parts, and seeds comprising the recombinant DNA molecules operably linked to heterologous transcribable DNA molecules, as are methods of their use.Type: GrantFiled: September 6, 2019Date of Patent: July 6, 2021Assignee: Monsanto Technology LLCInventors: Jaishree M. Chittoor, Stanislaw Flasinski, Mohammed Oufattole, Michael W. Petersen
-
Patent number: 11046967Abstract: The invention provides recombinant DNA molecules and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants. The invention also provides transgenic plants, plant cells, plant parts, and seeds comprising the recombinant DNA molecules operably linked to heterologous transcribable DNA molecules, as are methods of their use.Type: GrantFiled: September 6, 2019Date of Patent: June 29, 2021Assignee: Monsanto Technology LLCInventors: Jaishree M. Chittoor, Stanislaw Flasinski, Mohammed Oufattole, Michael W. Petersen
-
Patent number: 10989033Abstract: A treating tube may be positionable in a wellbore to create a passage internal to the treating tube and a passage in an annulus between the treating tube and a wellbore casing. Fluid may be injected into a fracturing zone from above or below a pay zone adjacent to the wellbore through a first of the two passages to expand the fracturing zone downhole or uphole, respectively, into the pay zone. Additional fluid may be injected into the pay zone through the second of the two passages to control the continued expansion of the pay zone into a desired shape. As proppant is routed through the first passage and deposited into the fractures, fluid flow in the second passage may be reversed to allow fluid to flow from the pay zone to the surface of the wellbore to control the placement of the proppant in the pay zone.Type: GrantFiled: November 2, 2015Date of Patent: April 27, 2021Assignee: Halliburton Energy Services, Inc.Inventors: Vladimir Nikolayevich Martysevich, Michael Wayne Sanders
-
Patent number: 10941444Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as lipoarabinomannan (LAM).Type: GrantFiled: January 30, 2019Date of Patent: March 9, 2021Assignee: Base Pair Biotechnologies, Inc.Inventors: George W. Jackson, Robert Batchelor, Rafal Drabek, Caitlin Bruns
-
Patent number: 10829753Abstract: The present invention relates to isolated polypeptides having protease activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: November 24, 2016Date of Patent: November 10, 2020Assignee: NOVOZYMES A/SInventors: Ye Liu, Xianzhi Jiang, Lan Tang, Astrid Benie, Henrik Frisner
-
Patent number: 10639280Abstract: The present invention relates to vaccine compositions based on Gram-negative outer membrane vesicles displaying antigens of pathogens expressed as part of a fusion protein comprising N-terminal parts of surface expressed lipoproteins of Gram-negative bacteria, and use of such compositions in vaccination. The invention further relates to the fusion lipoproteins comprising N-terminal parts of surface expressed lipoproteins of Gram-negative bacteria and antigens of pathogens fused thereto, DNA constructs and bacterial host cells for expressing these fusion lipoproteins and to methods for producing outer membrane vesicles displaying the fusion lipoproteins.Type: GrantFiled: June 2, 2016Date of Patent: May 5, 2020Assignee: DE STAAT DER NEDERLANDEN, VERT.DOOR DE MINISTER VAN VWS, MINISTERIE VAN VOLKSGEZONHEID, WELZIJN EN SPORTInventors: Merijn Louis Marten Salverda, Peter André Van Der Ley
-
Patent number: 10557142Abstract: The invention provides recombinant DNA molecules and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants. The invention also provides transgenic plants, plant cells, plant parts, and seeds comprising the recombinant DNA molecules operably linked to heterologous transcribable DNA molecules, as are methods of their use.Type: GrantFiled: July 30, 2018Date of Patent: February 11, 2020Assignee: Monsanto Technology LLCInventors: Jaishree M. Chittoor, Stanislaw Flasinski, Mohammed Oufattole, Michael W. Petersen
-
Patent number: 10443066Abstract: The invention provides recombinant DNA molecules and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants. The invention also provides transgenic plants, plant cells, plant parts, and seeds comprising the recombinant DNA molecules operably linked to heterologous transcribable DNA molecules, as are methods of their use.Type: GrantFiled: March 8, 2017Date of Patent: October 15, 2019Assignee: Monsanto Technology LLCInventors: Jaishree M. Chittoor, Stanislaw Flasinski, Mohammed Oufattole, Michael W. Petersen
-
Patent number: 9834773Abstract: Described are methods and means for metabolic engineering and improved product formation by a filamentous micro-organism or a low G+C gram-positive bacterium. Disclosed is that DasR and DasR binding sites play an important and universal role in the control of gene expression in micro-organisms. Based on this finding, provided are multiple useful applications, such as a method for regulating the expression of a gene of interest, a method for controlling metabolism, a method for decreasing undesired expression and many more. Moreover, provided are means that can be used to establish said methods: for example a micro-organism in which the DasR binding site in operable linkage with a particular gene has been modified to obtain increased or decreased expression of a protein (being a desired or undesired protein) encoded by said gene.Type: GrantFiled: February 14, 2007Date of Patent: December 5, 2017Assignees: Universiteit Leiden, University of Liège, Friedrich-Alexander-Universität Erlangen-NürnbergInventors: Sebastien Rigali, Mannfred Friedrich Bruno Titgemeyer, Gilles Philippus Van Wezel
-
Patent number: 9745575Abstract: The present invention refers to antagonist molecules, particularly nucleic acid effector molecules directed against a bacterial RNA.Type: GrantFiled: June 17, 2009Date of Patent: August 29, 2017Assignee: National University of SingaporeInventor: Volker Patzel
-
Patent number: 9446112Abstract: The invention relates to compositions and methods for treating C. difficile associated disease (CDAD) through the administration to a subject in need thereof at least one nucleic acid encoding at least a portion of at least one of toxin A and toxin B.Type: GrantFiled: July 12, 2012Date of Patent: September 20, 2016Assignees: Philadelphia Health & Education Corporation, Inovio Pharmaceuticals, Inc., The Trustees of the University of PennsylvaniaInventors: Michele Kutzler, Scott Baliban, David B. Weiner, Niranjan Y. Sardesai, J. Joseph Kim
-
Patent number: 9399673Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.Type: GrantFiled: March 5, 2013Date of Patent: July 26, 2016Assignees: Genentech, Inc., AIMM Therapeutics B.V.Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
-
Patent number: 9382546Abstract: There is described a method of synthesizing a family of oligopeptides of predetermined amino acid sequence, which together make up from 7 amino acids to the complete amino acid sequence of a target protein, which comprises: synthesizing a nucleic acid construct which codes for a fusion protein composed of overlapping peptides derived from the desired portion of the target protein, interspersed with regions which code for protease cleavage sites, expressing the nucleic acid construct in a suitable expression vector, harvesting the fusion protein corresponding to the nucleic acid sequence, and digesting the fusion protein with a protease selective for the cleavage sites to generate the oligopeptides. The oligopeptides may be generated in vitro or in vitro and may be used as vaccines against viral infections and in epitope mapping.Type: GrantFiled: April 30, 2007Date of Patent: July 5, 2016Assignees: ISIS INNOVATION LTD., DANA-FARBER CANCER INSTITUTE, INC.Inventors: Shisong Jiang, Ruth Ruprecht
-
Patent number: 9308248Abstract: The present invention relates to means and methods to protect against disease caused by bacteria belonging to the genus Chlamydia. In particular, the present invention relates to isolated B- and T-cell epitopes derived from the major outer membrane protein of Chlamydia psittaci which can be used against an infection with a species of the genus Chlamydia. More in particular, the invention provides a vaccine which can be used against chlamydiosis caused by Chlamydia psittaci in birds and man. In addition, the invention relates to a diagnostic method to diagnose the latter infections.Type: GrantFiled: June 15, 2012Date of Patent: April 12, 2016Assignee: Universiteit GentInventor: Daisy Vanrompay
-
Patent number: 9273307Abstract: The invention relates to global transcription machinery engineering to produce altered cells having improved phenotypes.Type: GrantFiled: October 15, 2013Date of Patent: March 1, 2016Assignee: Massachusetts Institute of TechnologyInventors: Hal S. Alper, Gregory Stephanopoulos
-
Patent number: 9249196Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: GrantFiled: January 26, 2012Date of Patent: February 2, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
-
Patent number: 9222110Abstract: The present invention relates generally to compositions and methods for producing lactic acid using a lactic acid producing microorganism. More specifically, the present invention relates to methods for producing lactic acid with high yield, high concentration and high volumetric productivity through biological fermentation by Enterococcus faecalis, or recombinant microorganisms transformed to produce lactate dehydrogenase using the lactate dehydrogenase-encoding genes derived from E. faecalis.Type: GrantFiled: December 17, 2013Date of Patent: December 29, 2015Assignee: South Dakota Board of RegentsInventors: Lew P. Christopher, Mohanraj Subramanian, Suvarna Naga Lavanya Talluri
-
Patent number: 9193771Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.Type: GrantFiled: October 17, 2013Date of Patent: November 24, 2015Assignee: MERZ PHARMA GmbH & CO. KGaAInventors: Fred Hofmann, Jurgen Frevert
-
Patent number: 9120868Abstract: A synthetic nucleotide, which transcribes as the cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen of Malaria Plasmodium, and methods of use thereof.Type: GrantFiled: November 23, 2009Date of Patent: September 1, 2015Assignee: The United States of America as Represented by the Secratary of the ArmyInventors: Evelina Angov, Elke Bergmann-Leitner, Christian Ockenhouse
-
Patent number: 9080191Abstract: The present invention relates to novel methods for biocatalytic production of nitriles from oximes using oxime dehydratases and novel mutants with oxime dehydratase activity and use thereof in a process for biocatalytic production of nitriles, such as in particular for the production of citral nitrile, neral nitrile, geranial nitrile or citronellyl nitrile from citral oxime, neral oxime, geranial oxime or citronellal oxime; and oxime dehydratases usable therefor, nucleotide sequences therefor and expression constructs or microorganisms comprising these.Type: GrantFiled: March 13, 2013Date of Patent: July 14, 2015Assignee: BASF SEInventors: Andrea Piatesi, Wolfgang Siegel, Kai-Uwe Baldenius
-
Publication number: 20150147332Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.Type: ApplicationFiled: September 26, 2014Publication date: May 28, 2015Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
-
Publication number: 20150140026Abstract: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.Type: ApplicationFiled: October 7, 2014Publication date: May 21, 2015Applicant: ARNE FORSGREN ABInventors: ARNE FORSGREN, KRISTIAN RIESBECK
-
Patent number: 9034642Abstract: The invention relates to the polynucleotide sequence of a nontypeable strain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.Type: GrantFiled: January 9, 2014Date of Patent: May 19, 2015Assignees: NATIONWIDE CHILDREN'S HOSPITAL, THE BOARD OF REGENTS OF UNIVERSITY OF OKLAHOMAInventors: Lauren O. Bakaletz, Robert S. Munson, Jr., David W. Dyer
-
Publication number: 20150135343Abstract: Certain embodiments are directed to polypeptide sensors. Certain aspects of the invention are directed to polypeptides for sensing or detecting GTP and GTP concentrations. In further aspects, the polypeptide sensor can measure GTP concentrations, with high temporal and spatial resolution.Type: ApplicationFiled: May 18, 2013Publication date: May 14, 2015Applicant: The Board of Regents of the University of Texas SyInventors: Rui Sousa, Mitra Rana
-
Publication number: 20150125503Abstract: The invention provides improvements of lantibiotics useful for reducing the numbers of microbes or the reproduction of microbes in or on subjects or objects. One embodiment of the invention provides variants of antibiotics wherein the amino acid at position (1) is changed to Ile or Gly, the amino acid at position (4) is changed to an Ala, the amino acid at position (4) is removed, the amino acid at position (5) is changed to an Ala, or wherein, as in the case of MU1140, the amino acid at position (13) is Arg, the Arg at position (13) is substituted with Asp, or combinations of two or more these changes or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 22, 2013Publication date: May 7, 2015Inventors: Jeffrey D. Hillman, James Leif Smith, Shawanda R. Wilson-Stanford
-
Patent number: 9024111Abstract: The present invention relates to nucleic acids, peptides, vectors, cells, and plants useful in the production of biofuels. In certain embodiments, the invention relates to nucleic acid sequences and peptides from extremophile organisms, such as SSO1949 and Ce1A, that are useful for hydrolyzing plant cell wall materials. In further embodiments, the invention relates to modified versions of such sequences that have been optimized for production in one or both of monocot and dicot plants. In other embodiments, the invention provides for targeting peptide production or activity to a certain location within the cell or organism, such as the apoplast. In further embodiments, the invention relates to transformed cells or plants. In additional embodiments, the invention relates to methods of producing biofuel utilizing such nucleic acids, peptides, targeting sequences, vectors, cells, and/or plants.Type: GrantFiled: March 30, 2012Date of Patent: May 5, 2015Assignee: Sandia CorporationInventors: Joseph S. Schoeniger, Masood Zia Hadi
-
Publication number: 20150111298Abstract: The present invention provides a tomaymycin biosynthetic gene cluster of Streptomyces species FH6421, and its use for producing 11-de-O-methyltomaymycin.Type: ApplicationFiled: May 13, 2013Publication date: April 23, 2015Applicant: SanofiInventors: Claus Lattemann, Mark Broenstrup, Stefan Werner, Rolf Müller, Kirsten Harmrols
-
Publication number: 20150111207Abstract: Sequences having specificity for Mycoplasma and related Mollicutes genus strains and uses thereof. Methods of use include detection of samples contaminated with Mycoplasma. Kits are provided and comprise one or more oligonucleotides for the detection of Mycoplasma and related Mollicutes genus strains.Type: ApplicationFiled: May 31, 2013Publication date: April 23, 2015Inventors: Claudia Zylberberg, Juan Manuel Rodriguez, Andres Clemente Hernando Insua, Ricardo Ariel Lopez
-
Patent number: 9011878Abstract: The present invention relates generally to vaccine strains of Brachyspira hyodysenteriae. In particular, the present invention relates to isolated live vaccine strains of B. hyodysenteriae lacking one or more virulence factors. The present invention also relates to methods of identifying and preparing vaccine strains, as well as vaccine compositions against diarrhoeal diseases and methods and kits for diagnosing same.Type: GrantFiled: November 13, 2009Date of Patent: April 21, 2015Assignee: Spirogene Pty LtdInventors: David J. Hampson, Tom La, Matthew I. Bellgard, Nyree D. Phillips
-
Publication number: 20150104476Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.Type: ApplicationFiled: September 16, 2014Publication date: April 16, 2015Applicant: CUREVAC GMBHInventors: Florian VON DER MÜLBE, Ingmar HOERR, Steve PASCOLO
-
Publication number: 20150105255Abstract: Derivatives of Agrobacterium vitis strain F2/5 are disclosed. These derivatives were generated following homologous recombination with an internal fragment of targeted genes resulting in gene disruption by insertion of a copy of suicide vector pVIK165. The genes disrupted were F-avi5813 encoding a phosphopantetheinyltransferase, F-avi4329 encoding an aminotransferase and F-avi0838 (rirA) encoding an iron responsive transcriptional regulator. Such derivatives control crown gall on grapevines. In addition, these derivatives did not induce roots necrosis but enhanced root development and callus formation. On young stem explants, it was shown as well that the F2/5 derivatives are necrosis-negative.Type: ApplicationFiled: March 15, 2013Publication date: April 16, 2015Applicant: Cornell UniversityInventors: Thomas J. Burr, Desen Zheng
-
Patent number: 8999669Abstract: The present invention relates to a nucleic acid molecule encoding a polypeptide specifically binding to proliferating cell nuclear antigen (PCNA). The present invention also relates to a vector comprising the nucleic acid molecule of the invention, a host cell comprising the nucleic acid molecule of or the vector of the invention and a method of detecting the amount and/or location of PCNA in living cells, a method of screening for compounds having an effect on the cell cycle.Type: GrantFiled: July 6, 2010Date of Patent: April 7, 2015Assignee: Ludwig-Maximilians Universitat MünchenInventors: Ulrich Rothbauer, Heinrich Leonhardt, Kourosh Zolghadr, Tina Romer, Katrin Schmidthals
-
Patent number: 8999667Abstract: The invention provides a DNA molecule comprising a multicistronic transcription unit coding for i) a polypeptide of interest, and for ii) a selectable marker polypeptide functional in a eukaryotic host cell, wherein the polypeptide of interest has a translation initiation sequence separate from that of the selectable marker polypeptide, and wherein the coding sequence for the polypeptide of interest is upstream from the coding sequence for the selectable marker polypeptide in the multicistronic transcription unit, and wherein an internal ribosome entry site is present downstream from the coding sequence for the polypeptide of interest and upstream from the coding sequence for the selectable marker polypeptide, and wherein the nucleic acid sequence coding for the selectable marker polypeptide in the coding strand comprises a GTG or a TTG start codon. Also provided are methods for obtaining host cells expressing a polypeptide of interest, such host cells comprising DNA molecules of the invention.Type: GrantFiled: September 6, 2007Date of Patent: April 7, 2015Assignee: Chromagenics B.V.Inventors: Arie P. Otte, Theodorus H. J. Kwaks, Henricus J. M. van Blokland, Richard G. A. B. Sewalt
-
Patent number: 8999641Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.Type: GrantFiled: March 26, 2014Date of Patent: April 7, 2015Assignees: The Broad Institute Inc., Maassachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana
-
Publication number: 20150093766Abstract: There is provided a diagnostic reagent useful to determine whether an animal has a tuberculosis infection or has been exposed to a tuberculosis agent, for example a Mycobacterium. The reagent is useful to distinguish between such an animal and an animal which has been vaccinated against a tuberculosis infection.Type: ApplicationFiled: September 23, 2014Publication date: April 2, 2015Inventors: Gareth JONES, Hans VORDERMEIER
-
Publication number: 20150093414Abstract: Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.Type: ApplicationFiled: December 2, 2014Publication date: April 2, 2015Inventors: Normand BLAIS, Anne-Marie GELINAS, James BROWN, Dennis MURPHY, Pascal METTENS
-
Publication number: 20150093413Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.Type: ApplicationFiled: February 15, 2013Publication date: April 2, 2015Applicant: CureVac GmbHInventors: Andreas Thess, Thomas Schlake, Jochen Probst
-
Patent number: 8993233Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.Type: GrantFiled: December 12, 2013Date of Patent: March 31, 2015Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana, Fei Ran
-
Patent number: 8993275Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: GrantFiled: February 12, 2013Date of Patent: March 31, 2015Assignee: Novozymes, Inc.Inventor: Nikolaj Spodsberg
-
Patent number: 8993839Abstract: Described herein are viral amplicon-based protein expression systems and methods useful for producing heterologous proteins, such as enzymes, by agroinfiltration. The methods involve producing an Agrobacterium with a Ti plasmid encoding a heterologous protein, infecting plant cells with the Agrobacterium, allowing expression of the heterologous protein, and recovering the heterologous protein from the plant cells. In one embodiment, the protein produced is an endoglucanase.Type: GrantFiled: July 19, 2011Date of Patent: March 31, 2015Assignee: The Regents of the University of CaliforniaInventors: Minsook Hwang, Benjamin E. Lindenmuth, Karen A. McDonald, Abhaya M. Dandekar, Bryce W. Falk, Sang-Kyu Jung, Nathaniel J. Kingsbury
-
Publication number: 20150087546Abstract: The invention relates to a sequence, a technique platform, and a method for in vitro detecting Clostridium difficile ribotype 027. The technology platform includes a pair of primers specific to C. difficile ribotype 027 and used for polymerase chain reaction (PCR), and primer sets as well as materials demanded for multiplex-PCR. The method comprises steps of obtaining a specimen DNA, in vitro amplifying the specimen DNA by the primer sets to detect whether the specimen is matched to characteristics of a target sequence of SEQ ID NO: 1. Specimen having a sequence matching to characteristics indicates that it comprises C. difficile ribotype 027. Accordingly, the present invention can achieve the aim at quickly confirming whether the specimen contains ribotype 027 strains.Type: ApplicationFiled: September 24, 2014Publication date: March 26, 2015Inventors: PEI-JANE TSAI, BO-YANG TSAI, YUAN-PIN HUNG, WEN-CHIEN KO